Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
CLOV vs OSCR: Weighing Two Tech-Driven Health Insurers

CLOV vs OSCR: Weighing Two Tech-Driven Health Insurers

Key Takeaways

  • Both CLOV and OSCR are technology-driven health insurers enjoying strong revenue growth and momentum, but they operate in different markets: CLOV focuses on Medicare Advantage seniors, while OSCR focuses on the Affordable Care Act (ACA) individual market.
  • OSCR is larger, more established, and already generating substantial profits, while CLOV is smaller and earlier in its profitability inflection, with faster relative membership growth.
  • OSCR has raised its full-year guidance multiple times in 2026, whereas CLOV is targeting its first full year of GAAP net income profitability.
  • Tickeron AI Verdict: OSCR is the favored ticker of the two, reflecting its demonstrated profitability at scale, more diversified footprint, and consistent upward revisions to guidance.
  • Explore deeper coverage by visiting CLOV Major News and CLOV Today's Price Move, as well as OSCR Major News and OSCR Today's Price Move.
  • To see how automated systems are positioning across these and thousands of other tickers, explore Trending AI Robots.

Introduction

Investors tracking the health insurance sector have increasingly turned their attention to two technology-enabled insurers: Clover Health Investments (CLOV) and Oscar Health (OSCR). Both companies pair insurance products with proprietary software platforms, yet they serve distinct customer bases and are at different stages of financial maturity. A stock comparison between the two is particularly relevant for growth-oriented traders and investors evaluating relative performance, market positioning, and the durability of recent momentum. Understanding how CLOV and OSCR differ in business model, catalysts, and risk profile can help clarify which name better fits current market conditions. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

CLOV Overview and Recent Performance

Clover Health Investments is a physician-enablement technology company that offers Medicare Advantage plans to seniors, powered by its Clover Assistant software platform, which aggregates patient data to support clinical decision-making. In recent weeks, CLOV has reported accelerating revenue and membership growth. For the third quarter, revenue rose roughly 53% year over year, and average Medicare Advantage membership grew about 46%, reaching approximately 159,000 members. Management has signaled confidence in delivering the company's first full year of GAAP net income profitability in 2026, supported by improving cohort economics, operating leverage, and a five-star rating on its flagship PPO plan for Payment Year 2028. The stock has shown notable volatility, and while momentum has strengthened, CLOV remains a smaller-capitalization name with a more concentrated geographic footprint, primarily in New Jersey and Georgia.

OSCR Overview and Recent Performance

Oscar Health is a technology-driven health insurer built on a full-stack platform, with its core business in the ACA individual and family insurance market, alongside products such as ICHRA solutions and its Lucie Health Marketplace. In recent market activity, OSCR has reported exceptional top-line growth, with third-quarter revenue rising about 72% year over year to approximately $5.1 billion, driven by premium rate increases, membership gains, and a favorable risk-adjustment adjustment. The company swung to a quarterly net profit, improved its medical loss ratio to 84%, and raised its full-year earnings outlook for the third time in 2026. With a footprint spanning more than 20 states and a much larger membership base, OSCR has drawn broad investor interest, though its profitability has been partly supported by one-time accounting benefits that warrant scrutiny. From what I see, this kind of consistent execution stands out.

Head-to-Head Comparison

The clearest contrast between the two companies is their market focus and scale. CLOV is concentrated in Medicare Advantage, a government-regulated senior market where its Clover Assistant platform and five-star quality ratings represent key competitive advantages, but where regulatory and geographic concentration present meaningful risks. OSCR operates in the ACA individual market, which is broader but highly sensitive to policy decisions such as premium tax credits and enrollment rules. In terms of growth drivers, CLOV is compounding membership and revenue more rapidly from a smaller base, while OSCR is scaling a much larger book and expanding its geographic footprint. On profitability, OSCR is further along, already reporting substantial net income, whereas CLOV is just reaching its first full-year of GAAP profitability. Sentiment has been favorable for both, but OSCR offers more established earnings visibility, while CLOV carries higher volatility and a more speculative profile.

Tickeron AI Verdict

Based on observable factors including trend consistency, earnings visibility, scale, and the cadence of positive guidance revisions, Tickeron's AI would currently lean toward OSCR as the relatively stronger choice between the two. Oscar Health's combination of demonstrated profitability, a more diversified state footprint, improving medical loss ratios, and repeated upward revisions to its outlook suggests a more stable and predictable earnings trajectory. Clover Health offers compelling growth and a genuine profitability inflection, but its smaller scale, geographic concentration, and higher volatility introduce comparatively more uncertainty. This assessment is probabilistic in nature and reflects current conditions rather than a definitive or guaranteed outcome. I’m watching this closely as conditions evolve.

Using AI Tools for Market Insights

In my analysis, I frequently review Tickeron’s AI Trading Bots to understand how automated strategies are positioning in names like these. The platform shows real-time performance data across hundreds of bots, helping identify which approaches align with current trends without relying on static models. This adds a useful layer when comparing opportunities such as CLOV and OSCR.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLOV, OSCR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CLOV in -3.81% downward trend, declining for three consecutive days on November 03, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CLOV declined for three days, in 281 of 330 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 56 cases where CLOV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLOV as a result. In 64 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for CLOV just turned positive on November 09, 2026. Looking at past instances where CLOV's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.

CLOV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLOV advanced for three days, in 225 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

CLOV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLOV's P/B Ratio (6.804) is slightly higher than the industry average of (3.520). P/E Ratio (-120.500) is within average values for comparable stocks, (126.353). CLOV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.970) is also within normal values, averaging (0.569).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating fairly steady price growth. CLOV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLOV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 16%. CVS experienced the highest price growth at 7%, while MOH experienced the biggest fall at 0%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -43%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 43
Price Growth Rating: 37
SMR Rating: 72
Profit Risk Rating: 83
Seasonality Score: -6 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ManagedHealthCare

Industry
N/A
Address
3401 Mallory Lane
Phone
+1 201 432-2133
Employees
724
Web
https://www.cloverhealth.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.
EUO is a leveraged inverse currency fund targeting -2x the daily performance of the euro versus the U.S. dollar, while XXX is a passive asset-allocation fund blending roughly 75% S&P 500 equities with 25% XRP exposure. The two funds are structurally unrelated: EUO is a tactical hedging and trading tool, whereas XXX is a diversified, long-biased growth vehicle.
CLOV vs OSCR: Weighing Two Tech-Driven Health Insurers